Introduction
As the HIV epidemic approaches its fourth decade, efective prevention remains elusive in the communities most afected by the virus. An estimated 36.9 million people were living with HIV globally by end 2014 [1] of whom 70% in sub-Saharan Africa. In 2014, an estimated 1.4 million people acquired HIV infection; 66% of these new infections and 66% of all HIV-related deaths occurred in sub-Saharan Africa, a region disproportionately afected by the epidemic. Remarkable strides have been made recently towards combating the epidemic and increasing antiretroviral therapy (ART) coverage with considerable reduction in mortality and morbidity [2] , such that in 2014, 40% of all people living with HIV were receiving ART. Following the results of the START [3] and TEMPRANO [4] trials, the World Health Organisation (WHO) now recommends ART regardless of CD4 count [5] , a policy that would maximise both the individual and population health beneit of ART. his aligns with the recent UNAIDS target of 90:90:90 (90% of people living with HIV aware of their HIV status, 90% of people diagnosed HIV-positive on ART, 90% of people on ART virologically suppressed) in 2020 [6] , but will require huge inancial investments and commitments from governments to bear fruit.
It is now well-recognised that prevention approaches need to be combined to accelerate the efective prevention of HIV acquisition and transmissions [7] ; HIV programme planning have now moved from the implementation of single preventive methods to combination contextspeciic prevention approaches, for which evidence of efectiveness exists.
his paper reviews currently available HIV prevention methods, highlighting the strengths and weaknesses of past prevention approaches, draws attention to the present array of prevention armamentarium available and conceptualises how these could be combined towards the goal of HIV elimination.
A 2010 review of behavioural intervention trials, with HIV incidence as main outcome, showed no signiicant reduction in HIV incidence in any of the nine randomised-controlled trials studied [9] . Project Accept (HPTN 043), is a cluster-randomised trial evaluating whether a multicomponent social and behavioural prevention approach could reduce HIV incidence. In this trial community-based versus facilitybased HIV counselling and testing showed no signiicant reduction in HIV incidence overall (relative risk [RR] 0·86, 95% CI 0·73-1·02) although there was a signiicant reduction in HIV incidence in he subgroup of women > 24 years of age (RR=0·70, 0·54-0·90) [10] .
Structural interventions
HIV-associated structural factors are deined as the physical, social, cultural, organizational, community, economic, legal or policy aspects of the environment that impede or facilitate persons' eforts to avoid HIV infection [11] For example, laws that discriminate against certain HIV risk groups such as men who have sex with men (MSM) or injecting drug users may stigmatise and hinder access to HIV prevention services. Similarly, cultural norms which perpetuate gender inequity may leave women economically dependent on men and unable to negotiate condom use for fear of abandonment [12] . Interventions addressing these factors tend to be complex and context-speciic; they do not seek to address risky behaviours directly, but address the prevailing circumstances which give rise to risky behaviours, acting on factors distal to the HIV outcome of interest. Distal factors may impact the outcome through multiple causal pathways making them diicult to evaluate; replication in other environments is challenging. One of the structural interventions receiving attention recently is the use of social cash transfers to encourage safer sex and a reduction in HIV acquisition. A randomised control trial in Lesotho using a lottery scheme as an incentive to reduce risky sexual behaviour showed a 25% (OR 0.75, 95% CI 0.58 -0.97) reduction in HIV incidence over 2 years [13] . A cluster randomised trial (CRT) in Malawi showed that cash incentives to young women and their households reduced HIV prevalence by 64% at 18 months; but making the payments conditional on school attendance made no diference to the reduction in HIV infection observed [14] . However a recently concluded CRT in South Africa showed that a conditional cash transfer to young women and men tied to HIV testing, participation in life skills training and academic attainment reduced the incidence of HSV-2 by 30% but did not have an impact on HIV incidence ater 24 months [15] . Similarly, another recently concluded randomised trial in South Africa found that cash transfer which is conditional on 80% school attendance by young women showed no reduction in HIV incidence ater 3 years [16] . hese results suggest that the efectiveness of social cash transfer could be context speciic.
Treatment of sexually transmitted infections (STIs)
Substantial evidence exists from observational studies suggesting an increased risk of HIV acquisition with both curable STIs and genital herpes [17, 18] . STIs have also been associated with increased HIV infectiousness, although this has not been quantiied directly in observational studies [19] . HIV-STI co-infection appears more likely to result in HIV transmission than infection with HIV alone [20, 21] However, nine randomised trials to date (four cluster randomised trials, two individual randomised trials on treating curable STIs and three individual randomised trials on Herpes suppressive therapy) have together failed to conirm the hypothesis that STI treatment would reduce HIV transmission and acquisition [19] . Of the four cluster-randomised trials examining the impact of STI treatment on HIV incidence, only the Mwanza trial in Tanzania showed syndromic treatment of STIs to be associated with a 40% signiicant reduction in HIV incidence [22] . Various factors may explain the diferences in efect between trials, including diferences in the HIV epidemic phase, enhanced interventions in the control group, and higher prevalence of STIs in the Mwanza trial compared to the other sites [19] .
Syndromic treatment of STIs focusses on patients presenting with symptoms, but provision of inadequate treatment and poor adherence could result in low efectiveness of syndromic treatment, which was estimated to be only 13% for curable STIs in rural KwaZulu-Natal [23] . Further, a signiicant proportion of STIs are asymptomatic [24] and the large pool of untreated individuals with asymptomatic STIs will continue to transmit HIV. his situation coupled with poor uptake of partner notiication could result in signiicant rates of STI reinfections and will likely impact HIV transmission and acquisition.
he efect of herpes simplex virus (HSV) suppressive therapy on HIV incidence has been evaluated in two randomised trials; the irst one in high-risk HSV-2 positive, HIV negative women in Tanzania [25] and the second involving women from three sites in Africa (Harare, Lusaka, Johannesburg) and MSM from Peru and the USA [26] . In these trials, treating HIV negative, HSV-2 positive individuals with aciclovir did not result in decreased HIV acquisition. A third randomised trial investigated the impact of HSV-2 suppressive therapy in HIV positive individuals on the risk of HIV transmission. Although suppressive therapy with acyclovir reduced HIV plasma viral load by about 0.25 log 10 and genital ulcers due to HSV-2 by 73%, there was no signiicant efect on HIV transmission (RR 0.92, 95% CI 0.60-1.41).
Although, these results are disappointing there remains compelling biological and epidemiological evidence that STIs are co-factors for HIV acquisition and transmission [27] and treatment of STIs should be part of the HIV care and prevention programme.
Male circumcision
A meta-analysis of 27 published observational studies on male circumcision in sub-Saharan Africa [28] provided evidence that male circumcision protects against HIV acquisition.
Male circumcision was shown to be protective against HIV acquisition in three randomised controlled trials in South Africa, Uganda and Kenya [29] [30] [31] ; in pooled analysis the combined incidence risk ratio (IRR) at 12 months was 0.50 (95% CI 0.34-0.72) and 0.46 (95% CI 0.34-0.62) at 21 or 24 months [32] .
hese observations in heterosexual HIV acquisition raised the question of whether this protection would also be observed in MSM. However, an observational analysis of data from a randomised controlled trial of HSV-2 suppressive therapy to prevent HIV acquisition found no evidence that circumcision was associated with reduced HIV incidence in MSM who practised predominantly insertive sex (RR 0.31, 95% CI: 0.06-1.51) [33] vaginal tenofovir gel). More adverse events due to genital lesions were reported in the nonoxynol-9 trials while these events were similar in both the microbicide and placebo arms of the other trials.
Antiretroviral treatment
he eicacy of antiretroviral therapy at preventing HIV transmission has been demonstrated in a variety of clinical scenarios such as in the prevention of mother-to-child [36, 37] , and heterosexual transmission [38] , which led to the declaration that an HIV infected individual who is on ART and has undetectable viral loads for at least 6 months with no STIs is sexually non-infectious [39] . Other uses include post-exposure prophylaxis in HIV-negative individuals ater occupational or sexual exposure to body luids from known or suspected HIV-positive individuals [40] [41] [42] [43] .
Oral and topical ART-based pre-exposure prophylaxis: More recently, studies have shown that ART could also be used by HIVnegative individuals prior to exposure to HIV to prevent HIV acquisition, known as pre-exposure prophylaxis (PrEP). Table 1 summarises the 11 trials on pre-exposure prophylaxis using
Non-ART vaginal microbicides
Initial research involving microbicides focused on non-ART related compounds, with a recent shit to ART-related compounds following multiple failures of the former to demonstrate efectiveness in the prevention of HIV acquisition in women.
hese earlier compounds were surfactants (nonoxynol-9) which disrupt the cell membranes of bacteria and viruses, polyanions (Carraguard, cellulose sulphate and PRO 2000) which interfere with the attachment of the virus to target cells in the mucosa and vaginal milieu, and protectors (BuferGel) which render the vagina acidic. In an acidic environment, sperms and viruses are inactivated or killed [34] . A recent meta-analysis of 13 randomised controlled trials involving 35,905 HIV negative women from Africa, India, hailand and the United States of America between 1996 -2011 showed no protective efects on HIV acquisition (RR 0.97, 95% CI: 0.87-1.08) [35] . his meta-analysis included mostly non-ART related microbicides; ive trials of nonoxynol-9, two trials of SAVVY, two of cellulose sulphate, one of Carraguard, one of PRO 2000 and one of BuferGel and one ART-related microbicide (CAPRISA 004 with 1% ART completed to date. he irst trial evaluating the efectiveness of once daily oral tenofovir for pre-exposure prophylaxis was conducted in three sites in Ghana, Cameroun and Nigeria among high risk HIVnegative women aged 18-35 years [44] . he Nigeria and Cameroun sites were closed prematurely for unspeciied reasons and as a result this trial lacked statistical power because of the small number of HIV seroconversions observed. In the CAPRISA 004, a proof-of-concept phase II trial including 889 HIV negative women, 1% tenofovir gel compared to placebo was shown to signiicantly decrease HIV acquisition, (RR 0.63, 95% CI 0.43-0.93) [45] . However, the results of three other PrEP trials, FEM-PrEP [46] , VOICE [47] and FACTS 001 [48] conducted in women have been very disappointing with none of them demonstrating any eicacy. Substudies of adherence within these large trials showed that there was poor adherence to the study drug which could explain the lack of eicacy observed.
he placebo arm of two other PreP trials -IPERGAY [49] and PROUD [50] -were terminated early because of marked reduction in HIV acquisition in the intervention arm compared to the placebo arm ART in HIV-discordant partnerships: Table 2 summarises the nine observational studies and one randomised-controlled trial evaluating the efectiveness of ART in preventing HIV transmission from the index to the HIV-uninfected partner. A Cochrane review and meta-analysis [56] of these observational studies identiied 2112 HIV transmissions: 1,016 among ART-treated couple and 1096 in those not taking ART. he combined rate ratio for the nine observational studies was 0.58 (95% CI: 0.17-0.75).
he one trial was a multicentre randomised-controlled trial (HPTN 052) [38] involving 1763 stable serodiscordant couples from 9 countries (Table 2) An earlier meta-analysis [57] When this meta-analysis was restricted to the two studies in which individuals had undetectable viral load, no transmission was recorded in 291 person years of follow up with an upper conidence limit of 1.27 per 100 person years.It is now established that ART is efective at preventing transmission in stable heterosexual couples, it remains unknown whether ART will be similarly efective at preventing HIV transmission at the population level. An observational study from rural KwaZulu-Natal suggests this to be the case [58] ; and this question is currently being addressed by four randomised trials [59] [60] [61] .
HIV vaccines
Recent HIV vaccine research has focused on antibody-based strategies following isolation of potent highly broadly neutralising monoclonal antibodies from infected individuals [71] . However, both arms of the adaptive immune system have important roles to play against HIV infection and or disease [71, 72] . Neutralising antibody response aim to prevent acquisition of HIV infection, while cytotoxic T lymphocytes (CTL) response, which only recognises infected host cells, could play a role in controlling viral replication and disease progression. It is unclear if robust CTL response can eradicate HIV infection in humans [71] .
Only one of the six HIV vaccine trials completed to date showed a protective eicacy (Table 3) .
he VAX004 (North America and the Netherlands) and VAX003 (hailand) were protein subunit trials using rgp120 monomers as immunogens aiming to elicit neutralising antibodies. Both failed to show signiicant protection against HIV acquisition [73, 74] .
Another vaccine approach is based on recombinant viral vectors engineered to express the gene of interest. he recombinant adenovirus serotype 5 was used as the vector for the Step (North and South America, the Caribbean and Australia) and Phambili (South Africa) trials [75, 76] . hese trials assessed the ability of these vaccines to stimulate the cellular immune responses. he Step trial was terminated early on the grounds of futility and lack of control of early viraemia in those who became infected. Enrolment in the Phambili trial was stopped because of the results observed in the Step trial.
he HVTN 505 (USA), was a phase 11b DNA vaccine trial that evaluated a DNA prime expressing Gag, Pol, Nef and Env with a recombinant adenovirus serotype 5 boost expressing Gag, Pol and Env. his trial was also halted prematurely for futility [77] .
he RV144 vaccine trial in hailand employed a combination of vaccine approaches [78] , comprising a canary pox viral vector prime expressing Env, Gag and Pol followed by a protein subunit vaccine boost (AIDSVAX B/E). he vaccine eicacy was 31% (95% CI, 1.1 to 52.1) ater 3.5 years. To date, this remains the only vaccine trial to demonstrate some protection against HIV acquisition.
Mathematical modelling
Mathematical modelling has played a pivotal role in the understanding of HIV pathogenesis by elucidating virus kinetics in terms of virus production and clearance from blood and CD4 T-lymphocytes depletion [80, 81] . his showed that HIV replicated at a very rapid rate and demonstrated the superiority of combination therapy over single drug therapy on virus kinetics. his early models also examined the role of long-lived and latently infected cell populations in the blood and the question as to whether combination therapy would be adequate to eradicate or cure HIV in an individual arose as a hypothesis. Later models have identiied third and fourth phase decays in HIV kinetics through the use of single copy assays [82] . his discovery as opposed to the initial two-phase decay proposed in earlier models implies that combination therapy may not be suicient to eliminate HIV within an individual.
Models have also played signiicant roles in generating important hypothesis about the impact of immediate ART on HIV elimination from the general population. he model by Granich et al. [83] generated a lot of interest in this regard. his model predicted that yearly HIV testing followed by immediate ART coupled with male circumcision, behaviour change programmes, condoms and treatment of STIs could reduce HIV incidence to less than one case per 1000 per year within 10 years and reduce the prevalence of HIV to less than 1% within 50 years. However the assumptions used to parameterise the model may be overly optimistic as the impact of such approaches have been shown by more recent models to be sensitive to factors such as uptake of HIV testing, linkage to care and ART coverage and the nature of the sexual networks [84] [85] [86] . here are challenges in achieving the sort of coverage required as illustrated by the leaks in the HIV care cascade described below.
Mathematical models, in combination with empirical research would play pivotal role in understanding interventions and their expected impact on HIV prevention and elimination.
Barriers to HIV Elimination

HIV care cascade
For ART to succeed as an efective HIV prevention method, there needs to be good coverage in all the steps of the HIV care pathway. he entry point into this pathway is HIV testing. hose testing HIVpositive need to be willing to initiate ART even when not clinically indicated for their own health, retained in care and be adherent lifelong.
Equally important are those who tested negative. hey should be aware of methods to protect themselves from HIV acquisition and be willing to test for HIV repeatedly for those who become HIV-positive to be linked to the care pathway.
HIV testing and linkage to care
HIV testing is necessary for linkage to HIV care and treatment. For HIV elimination, large numbers of individuals have to be willing to test for HIV regularly and those testing positive need to be linked to care and started on ART. However, despite the availability of efective treatment for HIV, 36% of individuals in SSA have never been tested for HIV [2] , with low perception of risk, concerns about conidentiality and fear of disclosure, stigma and discrimination suggested as explanations. Gender inequity that leaves women economically dependent on men may undermine the ability of women to seek HIV testing [87] [88] [89] .
Further, studies have shown a huge drop between the numbers of people taking an HIV test and linked to care. A systematic review and meta-analysis of eleven studies in SSA estimated that only 57% (95% CI, 48-66) of those diagnosed HIV positive are linked to care [90] . Another meta-analysis of studies in the USA estimated that 69% (95% CI, 66-71) of individuals diagnosed with HIV entered into care averaged over the time intervals from 1995 to 2009 [91] . Substantially higher numbers of individuals need to be linked to care for treatment assessment to realise the goal of HIV elimination. In a review of studies examining the barriers to linkage, the most commonly identiied factors include transport costs and distance to clinics. Others include concerns about disclosure and stigma, staf shortages, long clinic waiting times, male sex and younger age [92] .
Adherence/Retention in Care
he WHO deines adherence as "the extent to which a person's behaviour-taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider" [93] . Adherence to ART is vital for viral suppression [94] , which is important for optimal treatment outcomes and for prevention of HIV transmission [95] . Studies reporting on routine treatment programmes with difering ART initiation CD4 thresholds have shown that individuals starting treatment at higher CD4 counts are less likely to adhere consistently than individuals starting at lower CD4 counts [96, 97] . However in the HPTN 052 on stable sero-discordant couples, adherence measured by pill count of at least 95% was seen in 79% of participants in early therapy group (CD4 350-550 cells/mm
3 ) compared to 74% in the delayed therapy group (CD4<250 cells/mm 3 ) [38] . his may not be relective of real life situations. It remains to be seen how evidence from the START [3] and TEMPRANO [4] trials which suggest individual beneit to early ART would inluence adherence.
In the pre-exposure prophylaxis studies in which participants were aware that they were using the prescribed medications to prevent HIV transmission, adherence measured by drug levels was poor [46, 54] . A meta-analysis involving 37 qualitative and 47 quantitative studies on barriers and facilitators to adherence identiied fear of disclosure, concomitant substance abuse, forgetfulness, suspicions of treatment, complex regimens, high pill burden, decreased quality of life, work and family responsibilities, falling asleep and access to medications as the main adherence barriers [98] . Retention in HIV care takes two forms: pre-ART retention refers to retention in care of individuals not yet eligible for ART while retention on ART refers to individuals who remain in care ater initiating ART. A review of four studies in South Africa and one in Malawi estimated that the median proportion of patients retained in pre-ART care was 45% when CD4 eligibility threshold was 200 cells/mm 3 [90] . A review of 14 studies reporting proportions of patients retained in care from ART eligibility to ART initiation estimates a median of 68% (range 14-84%) [99] . For retention in care ater initiating ART, a systematic review of 33 studies reporting on 39 patient cohorts estimated that 65% of patients are retained in ART care (range 58%-72%) ater 36 months [100] . Factors that impact retention in care include challenges that relate to housing, transportation to clinics, mental health and drug abuse which would need to be addressed in afected individuals. Provider-patient relationship and clinic opening hours are other issues that need to be addressed to improve retention in care [91] .
Virological failure and drug resistance
Initiation of treatment early in the course of infection before symptoms develop results in large proportions of HIV-infected individuals on ART; if adherence is indeed sub-optimal, this could lead to signiicant rates of virological failure and the likely development of drug resistance. Studies in sub-Saharan Africa of people who started treatment on the basis of conservative guidelines showed that 15-25% of patients had HIV-RNA >400 copies/mL 6-36 months ater starting ART [101] , consistent with indings from the Hlabisa HIV Treatment and Care programme with an estimated 15% of patients having HIV RNA >400 copies/mL 12 months ater starting ART [102] . A further study from this latter cohort showed that 86% of individuals failing irst-line ART with detectable VL had at least one drug-resistant mutation [103] with high levels of NNRTI-(83%) and NRTI-(81%) associated mutations; the median time spent on a failing regimen was 27 months (IQR 17-41). he long duration spent on failing ART with accumulation of resistant mutations could be a possible explanation for the 15% of patients with virological failurewhose second-line regimen was compromised.
With increasing exposure of larger numbers of people to longer durations of ART, those developing ART resistance could potentially transmit resistant virus to their sexual partners, which would result in increasing numbers of new infections due to resistant virus [104, 105] . A recent evaluation of transmitted resistance in 11 regions in six subSaharan African countries including South Africa estimated prevalence of transmitted drug resistance in South Africa of 1.1%, but 12.3% in Kampala, Uganda [106] . Increasing prevalence of transmitted resistance would necessitate more complex and more expensive irstline regimen which could impact on adherence and result in lack of virological suppression and increased transmissions making HIV elimination diicult.
Risk compensation
HIV has become a chronic condition, and some individuals may be less concerned about HIV than thirty years ago [107] , which, coupled with the knowledge that ART may prevent HIV transmission, could lead to increased high risk sexual behaviour, known as risk compensation. However, studies in resource-limited settings with high HIV prevalence have not shown an increase in risky sexual behaviour amongst individuals initiating ART. In a Ugandan study , an increase in sexual activity following ART was accompanied by a 70% reduction in the number of unprotected sexual acts with a partner known to be HIV negative or of unknown serostatus [108] . In a longitudinal study in South Africa on HIV-infected individuals with pre-ART and post-ART follow-up over seven years, high risk sexual behaviour following ART initiation was reduced [109] . A recent ecological study from a rural South African surveillance site found no evidence of an increase in high risk sexual behaviour at the population level following the expansion of ART availability, instead there was an increase in reported condom use at last sex with regular partners [110] .
However, many studies in MSM in the developed world have shown an increase in high risk sexual behaviour following the introduction of ART coinciding with an increase in HIV incidence [111, 112] . Whilst the frequency of HIV testing increased during this period, this was not suicient to account for the observed increase in the number of new diagnoses [112] .
As ART roll-out in sub-Saharan Africa is relatively recent, it is important to maintain on-going surveillance in risk behaviour in this region as this may change as more people become aware of the beneit of ART to prevent transmission.
Conclusion
Remarkable strides have been made in the past decade in potentially curbing the HIV epidemic, although numbers of new infections remain unacceptably high. No HIV prevention approach is 100% eicacious; all require behaviour change as individuals need to have the agency to decide which of the prevention methods best meet their needs at any particular point in time. he optimal way to tackle the epidemic is likely to be through combination HIV prevention [113, 114] , which combines behavioural change, treatment of STIs, ART for HIV positives and for pre-exposure prophylaxis for HIV negatives, male medical circumcision and structural approaches (Figure 1 ). It is now recognised that even within generalised epidemics, there are many microepidemics, hence interventions need to be focussed in nature by targeting areas of high transmission geographies and people at most risk of infections including key populations [115] Which and how these interventions are combined may vary by setting using the "know your epidemic, know your response" concept [116] . A modelling study calibrated using the Kenyan HIV epidemic showed that combination of interventions which are deployed in a focused manner as opposed to a uniform manner with a ixed budget applied to both scenarios resulted in more substantial decrease in the incidence of HIV infections [117] . his focused intervention approach requires that the HIV epidemic in a particular setting is characterised to subnational level.he partner demonstration project, which included high risk serodiscordant couples in Kenya and Uganda combined ART given to the HIV positive partner with PrEP given to the HIV negative partner resulted in a 96% reduction in HIV transmission from the HIV positive to the HIV-negative partner.
Research is needed into how the cascade of care can be strengthened from the point of HIV testing to linkage of individuals to care and virological suppression. his would be necessary steps to maximise the impact the new WHO guidelines which recommend ART regardless of CD4 count [5] .
Factors which act as barriers and facilitators for each step of the cascade need to be understood both at the individual and health care system level so that appropriate interventions can be put in place.
Novel drug formulations that require infrequent administration would be a welcome addition to the HIV prevention armamentarium, as this strategy has the potential to increase adherence [118] .
Although the HIV vaccine ield has been disappointing with no suiciently eicacious vaccine currently available, lessons have been learnt from the research with improved insight as to how HIV evades the immune system. his is not the time to relax, rather to intensify eforts in this area because an eicacious preventive vaccine would be required in addition to other biomedical intervention in order to make HIV elimination an attainable goal. he vaccine eicacy required to achieve this would need to be modelled in combination with other prevention approaches [119] . Substantial investments with smart health-inancing, integrating of health services and political commitment would be required to achieve the goal of HIV elimination [119] . 
